FDA shoots down Spectrum's neutropenia drug, citing manufacturing issues

In another setback for Spectrum Pharmaceuticals, the FDA has rejected its lead drug for neutropenia in patients receiving cancer drugs.

The company said Friday the CRL from the FDA cited manufacturing deficiencies, indicating that a reinspection will be necessary of the South Korea-based Hanmi Bio Plant that makes the drug, known as Rolontis (eflapegrastim).